CANM/ACMN – Guidelines for imaging of the dopamine transport system in evaluation of movement disorders

Click here : CANM – Guidelines

Document prepared by Drs. Alfonso Fasano, Ruban Gnanakumar, Heather Rigby, Andrew Ross, Jean-Paul Soucy, Alex Tamm -January 2020

In the investigation of movement disorders in which Dopamine transporter loss is a potential component, most commonly Parkinsonism, and there is diagnostic uncertainty, imaging           with         123I-ioflupane      can         provide  important information. As a Health Canada approved imaging agent is now available, the Canadian Association of Nuclear Medicine has produced this set of guidelines to aid clinicians in utilizing and performing the test in the evaluation and treatment of

Canadian patients. It has been produced by a group of expert Nuclear Medicine Physicians and Movement Disorder Neurologists assessing best practices in Canada, Europe and the United States.